OraSure Technologies, a point-of-care diagnostic tests provider, announced that its OMNIgene ORAL (OME-505) saliva collection device, a product of its subsidiary DNA Genotek, has been authorised by Health Canada for use in molecular diagnostic tests for detecting the SARS-CoV-2 virus. The move will facilitate the expansion of Covid-19 testing programmes in the country.
Mammoth Biosciences, a company that uses gene-editing technology Crispr for disease testing, announced that it has signed a co-marketing agreement with Agilent Technologies, an analytical instrumentation development and manufacturing company, to launch a CRISPR-based SARS-CoV-2 diagnostic solution. As per the partnership, the Agilent will offer its Bravo automation workstation and Mammoth its DETECTR BOOSTTM assay.
Eurofins Technologies and Eurofins Genomics have announced the launch of two validated assays for detecting B.1.1.7 (UK) and B.1.351 (South Africa) variants of the SARS-CoV-2 virus within a short turn-around time. The GSD NovaType SARS-CoV-2 Detect & ID is a real-time RT-PCR test that detects the SARS-CoV-2 virus, along with the UK and South Africa variants.
Avacta, a biotherapeutics company, has collaborated with Bruker Corporation, an analytical instrumentation manufacturer, to evaluate the Affimer-based, bead-assisted mass spectrometry SARS-CoV-2 assay that it developed with Adeptrix, an analytical reagents and assays developer. The collaboration will assess the suitability of the test as an in-vitro diagnostic product for SARS-CoV-2 infection that is expected to be run on Bruker’s MALDI-TOF instruments.